Perspective Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 28, 2024
CATX$0.86+1.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
Perspective Therapeutics, Inc. and Subsidiaries
Consolidated Balance Sheets
(In thousands, except shares)
| December 31, | December 31, | |
|---|---|---|
| 2023 | 2022 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $9,238 | $20,993 |
| Short-term investments | - | 22,764 |
| Accounts receivable, net | 1,165 | 1,363 |
| Note receivable | - | 6,109 |
| Prepaid expenses and other current assets | 1,133 | 443 |
| Current assets held for sale - discontinued operations | 5,301 | 1,543 |
| Total current assets | 16,837 | 53,215 |
| Noncurrent assets: | ||
| Property and equipment, net | 5,576 | 371 |
| Right of use asset, net | 747 | - |
| Restricted cash | 182 | 182 |
| Intangible assets: In-process research and development | 50,000 | - |
| Goodwill | 24,062 | - |
| Other assets, net | 487 | 175 |
| Noncurrent assets of discontinued operations | - | 4,148 |
| Total assets | $97,891 | $58,091 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||
| Current liabilities: | ||
| Accounts payable and accrued expenses | $6,107 | $1,541 |
| Lease liability | 46 | - |
| Accrued protocol expense | 322 | 233 |
| Accrued radioactive waste disposal | 480 | 571 |
| Accrued payroll and related taxes | 3,128 | 212 |
| Accrued vacation | 460 | 285 |
| Note payable, current | 49 | - |
| Current liabilities of discontinued operations | 5,072 | 276 |
| Total current liabilities | 15,664 | 3,118 |
| Noncurrent liabilities: | ||
| Lease liability | 780 | - |
| Notes payable | 1,676 | - |
| Noncurrent liabilities of discontinued operations | - | 331 |
| Deferred tax liability | 4,592 | - |
| Total liabilities | 22,712 | 3,449 |
| Commitments and contingencies (Note 16) | ||
| Stockholders' equity: | ||
| Preferred stock, $.001 par value; 7,000,000 shares authorized: Series B: 5,000,000 shares allocated; no shares issued and outstanding | - | - |
| Common stock, $.001 par value; 750,000,000 shares authorized; 281,809,852 and 142,112,766 shares issued and outstanding | 282 | 142 |
| Additional paid-in capital | 227,337 | 160,432 |
| Accumulated deficit | (152,440) | (105,932) |
| Total stockholders' equity | 75,179 | 54,642 |
| Total liabilities and stockholders' equity | $97,891 | $58,091 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.